Mainolfi Nello 4

What Happened
Nello Mainolfi, CEO of Kymera Therapeutics (KYMR), exercised stock options to acquire 50,000 shares at $2.08 per share (cost ≈ $104,000) and sold 50,000 shares in an open-market transaction at $119.00 per share for total proceeds of $5,950,000. The filing also reports two derivative conversion/disposition entries (45,559 and 4,441 shares) recorded at $0.00 each; these are listed as exercise/conversion of derivatives rather than open-market sales.

Key Details

• Transaction date: 2026-07-07
• Option exercise: 50,000 shares acquired @ $2.08 = $104,000
• Open-market sale: 50,000 shares sold @ $119.00 = $5,950,000
• Additional derivative dispositions: 45,559 shares and 4,441 shares recorded at $0.00 (reported as exercises/conversions)
• Footnotes: Transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 (F1). The shares underlying the option are fully vested and exercisable (F2).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: No late-filing flag provided in the information supplied.

Context
This shows an option exercise followed by an immediate sale of the same number of shares; Mainolfi paid a modest exercise price ($2.08) and sold at market ($119), yielding substantial proceeds. Trades executed under a 10b5-1 plan are pre-planned and typically indicate pre-set selling instructions rather than ad-hoc decisions. As always, insider sales can be routine (liquidity/tax reasons); they are not definitive indicators of company prospects.